I am a pulmonary & critical care physician-scientist whose interests focus on the intersection between clinical risk-prediction models and genomic markers to improve pulmonary fibrosis outcomes.
Pulmonary fibrosis is a destructive interstitial lung disease characterized by profound scarring. In severe pulmonary fibrosis, death generally ensues within three to five years. Recent genomic advances have identified factors that influence heterogeneity and prognosis in pulmonary fibrosis. However, healthcare disparities and the exclusion of major racial groups from these genetic studies limits the generalizability of their findings. My work leverages advanced statistical techniques to improve the delivery of high-quality care in patients with fibrotic lung diseases. Much of my research is aimed at identifying improved practical strategies to optimize pharmacotherapy in patients with pulmonary fibrosis.
The main thrust of my work is currently on utilizing genetic data from diverse races to improve clinical decision-making and outcomes for all patients with pulmonary fibrosis.
Acute exacerbation in fibrotic interstitial lung disease: an international working group report.
Acute exacerbation in fibrotic interstitial lung disease: an international working group report. Am J Respir Crit Care Med. 2026 Oct 01; 212(10):2358-2385.
PMID: 42447235
Mycophenolate and azathioprine in fibrotic interstitial lung disease.
Mycophenolate and azathioprine in fibrotic interstitial lung disease. Am J Respir Crit Care Med. 2026 Oct 01; 212(10):2493-2503.
PMID: 42432856
Performance of age-adjusted whole genome sequencing telomere length in idiopathic pulmonary fibrosis.
Performance of age-adjusted whole genome sequencing telomere length in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2026 Oct 01; 212(10):2445-2454.
PMID: 42261270
Markers of microvascular instability predict severity and survival in idiopathic pulmonary fibrosis.
Markers of microvascular instability predict severity and survival in idiopathic pulmonary fibrosis. Thorax. 2026 Sep 10.
PMID: 42722423
Updated European Respiratory Society-American Thoracic Society (ERS-ATS) Classification of Interstitial Pneumonias: The Radiologic Perspective.
Updated European Respiratory Society-American Thoracic Society (ERS-ATS) Classification of Interstitial Pneumonias: The Radiologic Perspective. Radiology. 2026 Sep; 320(3):e253791.
PMID: 42808894
Reply to Vasakova: Bronchiolocentric interstitial pneumonia as a new IP entity causes more chaos than advancement.
Reply to Vasakova: Bronchiolocentric interstitial pneumonia as a new IP entity causes more chaos than advancement. Am J Respir Crit Care Med. 2026 Aug 17.
PMID: 42608471
Reply to Morell: Hypersensitivity Pneumonitis included in Bronchiolocentric Interstitial Pneumonia.
Reply to Morell: Hypersensitivity Pneumonitis included in Bronchiolocentric Interstitial Pneumonia. Am J Respir Crit Care Med. 2026 Aug 08.
PMID: 42572901
Comprehensive assessment of complete blood count as a prognostic biomarker in interstitial lung diseases.
Comprehensive assessment of complete blood count as a prognostic biomarker in interstitial lung diseases. Respir Med. 2026 Oct; 262:109086.
PMID: 42567369
Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasets.
Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasets. Eur Respir J. 2026 Jul; 68(1).
PMID: 42167781
Longitudinal Mediastinal Lymph Node Dynamics Associate With Mortality and Fibrosis Progression in Fibrotic Interstitial Lung Disease.
Longitudinal Mediastinal Lymph Node Dynamics Associate With Mortality and Fibrosis Progression in Fibrotic Interstitial Lung Disease. Chest. 2026 Jul 07.
PMID: 42413723